Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Studies of Interaction of Tumor Suppressor P53 with Apo-Mt Using Surface Plasmon Resonance

Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network

Expression, purification, and in vitro mitochondrial interaction analysis of full-length and truncated human tumor suppresser p53

Interaction Between P53 and TRF1、TRF2 and Analysis of Binding Domain of P53 in vitro

In Vitro Binding of P53 and Telomeric Repeat Factor 2

Molecular dynamics-based computational investigations on the influence of tumor suppressor p53 binding protein against other proteins/peptides

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Single Molecule Study of the Weak Biological Interactions Between P53 and Dna

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

[The Molecular Interaction Between P53 and Telomeric Repeat Binding Protein 1 in Vitro].

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

Basal and copper-induced expression of metallothionein isoform 1,2 and 3 genes in epithelial cancer cells: The role of tumor suppressor p53

Sensitive sandwich-type electrochemical immunosensing of p53 protein based on Ti3C2Tx MXene nanoribbons and ferrocene/gold

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Identification of mutant p53-specific proteins interaction network using TurboID-based proximity labeling

Systematic Mutational Analysis of Peptide Inhibition of the P53-Mdm2/Mdmx Interactions

Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation

A Comparative Study on Interactions of Cisplatin and Ruthenium Arene Anticancer Complexes with Metallothionein Using MALDI-TOF-MS

Global Investigation of p53-induced Apoptosis Through Quantitative Proteomic Profiling Using Comparative Amino Acid-coded Tagging

Dual‐Targeting Nanovesicles for in Situ Intracellular Imaging of and Discrimination Between Wild‐type and Mutant P53

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer